Hyaluronan: Pharmaceutical characterization and drug delivery

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 12, Issue 6, 2005, Pages 327-342

  Liao, Yong Hong ^a   Jones, Stuart A ^b   Forbes, Ben ^b   Martin, Gary P ^b   Brown, Marc B ^b  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Analysis; Drug Delivery; Hyaluronan; Physiochemical Properties; Topical

Indexed keywords

ACECLIDINE; AGENTS ACTING ON THE EYE; ARECAIDINE PROPARGYL ESTER; BETA GLUCURONIC ACID; BINDING PROTEIN; BIONECT; CELL SURFACE RECEPTOR; CONNETTIVINA; CORTICOSTEROID; DESMOPRESSIN; DICLOFENAC; DOXORUBICIN; EMBRYOGLUE; GENTAMICIN; HYALURONIC ACID; INSULIN; JOSSALIND; N ACETYLGLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPEGAN; OPELEAD; PACLITAXEL DERIVATIVE; PILOCARPINE; SUPEROXIDE DISMUTASE; TOBRAMYCIN; TROPICAMIDE; UNCLASSIFIED DRUG; VASOPRESSIN; XYLOMETAZOLINE;

ACTINIC KERATOSIS; BACTERIAL CELL WALL; BIOCOMPATIBILITY; CANCER INVASION; CELL REGENERATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG STRUCTURE; IMMUNOGENICITY; MORPHOGENESIS; NIDATION; OSTEOARTHRITIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; VISCOELASTICITY; WOUND HEALING;

ANIMALS; CARBOHYDRATE SEQUENCE; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EMBRYO IMPLANTATION; GENE THERAPY; HUMANS; HYALURONIC ACID; LIPOSOMES; MOLECULAR SEQUENCE DATA; OPHTHALMIC SOLUTIONS; OSTEOARTHRITIS; SKIN DISEASES; VEHICLES; WOUND HEALING;

EID: 27644576663     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540590952555     Document Type: Review

References (219)

1. European Pharmacopoeia. 2002. Strasbourg: European Pharmacopoeia Commission.
2. Abeydeera, L. R. 2002. In vitro production of embryos in swine. Theriogenology 57:257-273.
3. Adam, N., and Ghosh, P. 2001. Hyaluronan molecular weight and polydispersity in some commercial intra-articular injectable preparation and in synovial fluid. Inflamm. Res. 50:294-299.
4. Adams, M. E., Lussier, A. J., and Peyron, J. G. 2000. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf. 23:115-130.
5. Altman, R. D. 2000. Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin. Arthritis Rheum. 30:11-18.
6. Amr, S. K. 2000. The effect of homogenised skin on the activity of licosamde antibiotics. Proc. Millen. Cong. Pharma. Sci. A80.
7. Armstrong, S. E., and Bell, D. R. 2002. Measurement of high-molecular-weight hyaluronan in solid tissue using agarose gel electrophoresis. Anal. Biochem. 308:255-264.
8. Arnott, S., Mitra, A. K., and Raghunathan, S. 1983. Hyaluronic-acid double helix. J. Mol. Biol. 169:861-872.
9. Asteriou, T., Deschrevel, B., Delpech, B., Bertrand, P., Bultelle, F., Merai, C., and Vincent, J. C. 2001. An improved assay for the n-acetyl-glucosamine reducing ends of polysaccharides in the presence of proteins. Anal. Biochem. 293:53-59.
10. Balazs, E. A., Cowman, M. K., and Briller, S. O. 1983. On limiting viscosity number of hyaluronate in potassium phosphate buffers between pH 6.5 and 8. Biopolymers 22:589.
11. Balazs, E. A. 1998. The viscoelastic intracellular matrix and control of eel function by hyaluronanl. In The chemistry, Biology and Medical Applications of Hyaluronan and Its Derivatives, ed. T. C. Laurent, 185-204. London: Portland Press.
12. Balazs, E. A. 2003. Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs 174:49-62.
13. Balazs, E. A., and Denlinger, J. L. 1989. Clinical uses of hyaluronan. Ciba Foundation Symposia 143:265-280.
14. Balazs, E. A., and Denlinger, J. L. 1993. Viscosupplementation: a new concept in the treatment of osteoarthritis. J. Rheumatol. 20:3-9.
15. Band, P. A. 1998. Hyaluronan derivatives: chemistry and clinical applications. In The Chemistry, Biology and Medical Applications of Hyaluronan and its derivatives, ed. T.C.Laurent, 33-42, London: Portland Press.
16. Banerji, S., Ni, J., Wang, S. X., Clasper, S., Su, J., Tammi, R., Jones, M., and Jackson, D. G. 1999. LYVE-I, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144:789-801.
17. Banks, J., Kreider, J. W., Bhavanadan, V. P., and Davidson, E. A. 1976. Anionic polysaccharide production and tyrosine activation in clutured human melanima cells. Cancer Res. 36:424-431.
18. Barrett, J. P., and Siviero, P. 2002. Retrospective study of outcomes in Hyalgan (R)-treated patients with osteoarthritis of the knee. Clin. Drug Invest. 22:87-97.
19. Basedow, A. M., and Ebert, K. 1977. Ultrasonic degradation of polymers in solution. Adv. Polymer Sci. 22:83-148.
20. Beaty, N. B. 1985. Relative molecular weight and concentration determination of sodium hyaluronate solutions by gel-exclusion high-performance liquid chromatography. Anal. Biochem. 147:387-395.
21. Bernatchez, S. F., Tabatabay, C., and Gurny, R. 1993. Sodium hyaluronate 0.25-percent used as a vehicle increases the bioavailability of topically administered gentamicin. Graefes Arch. Clin. Exp. Ophthalmol. 231:157-161.
22. Bitter, T., and Muir, H. M. 1962. A modified uronic acid reaction. Anal. Biochem. 4:330-334.
23. Blumberg, B. S. 1954. Light-scattering studies on hyaluronic acid. Science 120:432-433.
24. Braun, D. P., Taylor, S. G., and Hams, J. E. 1989. Modulation of immunity in cancer patients by prostaglandin antagonists. In Immunity to Cancer II, ed. R. Alan, 439-448. New York: Liss Inc.
25. Brown, M. B., Forbes, B., and Martin, G. P. 2002. The use of hyaluronan in topical drug delivery. In Hyaluronan: Biomedical. Medical and Clinical Aspects, eds. J. Kennedy, G. O. Phillips, P. A. Williams, and V. Hascall, 249-256. Cambridge: Woodhead Publishers.
26. Brown, M. B., Ingham, S., Moore, A., Marriott, C., and Martin, G. P. 1995a. A preliminary study of the effect of hyaluronan in drug delivery. In Hyaluronan in Drug Delivery, ed. D. A. Willoughby, 48-52. London: Royal Society of Medicine Press.
27. Brown, M. B., Marriott, C., and Martin, G. P. 1995b. A study of the transdermal drug delivery properties of hyaluronan. In Hyaluronan in Drug Delivery, ed. D. A. Willoughby, 53-71, London: Royal Society of Medicine Press.
28. Brown, M. B., Marriott, C., and Martin, G. P. 1995c. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int. J. Tissue Reactions-Exp. Clin. Aspects 17:133-140.
29. Brown, M. B., and Martin, G. P. 2001. Comparison of the effect of hyaluronan and other polysaccharides on drug skin partitioning. Int. J. Pharm. 225:113-121.
30. Brown, M. B., and Moore, A. 1996. The effects of a novel formulation of cyclosporin on antibody and cell-mediated immune reactions in the pleural cavity of rats. In Hyaluronan in Drug Delivery, ed. D. A. Willoughby, 121-131. London: Royal Society of Medicine Press.
31. Brown, T. J., Alcorn, D., and Fraser, J. R. E. 1999. Absorption of hyaluronan applied to the surface of intact skin. J. Invest. Dermatol. 113:740-746.
32. Brunda, M. J., Herberman, R. B., and Holden, H. I. 1980. Inhibition of munne natural killer cell activity by prostaglandins. J. Immunol. 124:2682-2687.
33. Bucolo, C., and Mangiafico, P. 1999. Pharmacological profile of a new topical pilocarpine formulation. J. Ocul. Pharmacol. Ther. 15:567-573.
34. Bucolo, C., Spadaro, A., and Mangiafico, S. 1998. Pharmacological evaluation of a new timolol/pilocarpine formulation. Ophthalmic Res. 30:101-106.
35. Budiaman, E. R., and Fennema, O. 1987. Linear rate of water crystallization as influenced by temperature of hydrocolloid suspensions. J. Dairy Sci. 70:534-546.
36. Camber, O., and Edman, P. 1989. Sodium hyaluronate as an ophthalmic vehicle-some factors governing its effect on the ocular absorption of pilocarpine. Curr. Eye Res. 8:563-567.
37. Camber, O., Edman, P., and Gurny, R. 1987. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Curr. Eye Res. 6:779-784.
38. Campoccia, D., Doherty, P., Radice, M., Brun, P., Abatangelo, G., and Williams. D. F. 1998. Semi-synthetic restorable materials from hyaluronan esterification. Biomaterials 19:2101-2127.
39. Cantor, J. O., Cerreta, J. M., Armand, G., and Turino, G. M. 1998. Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase. Proc. Soc. Exp. Biol. Med. 217:471-475.
40. Castellano, F., and Mautone, G. 2002. Decongestant activity of a new formulation of xylometazoline nasal spray: a double-blind, randomized versus placebo and reference drugs controlled, dose-effect study. Drugs Exp. Clin. Res. 28:27-35.
41. Chaidedgumjorn, A., Suzuki, A., Toyoda, H., Toida, T., Imanari, T., and Linhardt, R. J. 2002. Conductivity detection for molecular mass estimation of per-O-sulfonated glycosaminoglycans separated by high-performance size-exclusion chromatography. J. Chromatogr. A 959:95-102.
42. Cichy, J., and Pure, E. 2003. The liberation of CD44. J. Cell Biol. 161:839-843.
43. Cleland, R. L., and Wang, J. L. 1970. Ionic polysaccharides. III. Dilute solution properties of hyaluronic acid fractions. Biopolymers 9:799.
44. Cowman, M. K., Liu, J., Hittner, D. M., and Kim, J. S. 1998. Hyaluronan interactions: salt, water, ions.' In The Chemistry. Biology and Medical Applications of Hyaluronan and Its Derivatives, ed. T. C. Laurent, 17-25. London: Portland Press.
45. Day, A. J., and Prestwich, G. D. 2002. Hyaluronan-binding proteins: tying up the giant. J. Biol. Chem. 277:4585-4588.
46. Day, A. J., and Sheehan, J. K. 2001. Hyaluronan: polysaccharide chaos to protein organisation. Curr. Opin. Struct. Biol. 11:617-622.
47. Del Rosso, J. Q. 2003. New and emerging topical approaches for actinic keratoses. Cutis 72:273.
48. Denlinger, J. L. 1998. Hyaluronan and its derivatives as viscoelastics in medicine. In The Chemistry. Biology and Medical Applications of Hyaluronan and Its Derivatives, ed. T. C. Laurent, 235-242. London: Portland Press.
49. Doherty, M. M., Hughes, P. J., Kim, S. R., Mainwaring, D. E., and Charman, W. N. 1994. Effect of lyophilization on the physical characteristics of medium molecular-mass hyaluronates. Int. J. Pharm. 111:205-211.
50. Dougados, M. 2000. Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect. Semin. Arth. Rheum. 30:19-25.
51. Drobnik, J. 1991. Hyaluronan in drug delivery. Adv. Drug Dev. Rev. 7:295-308.
52. Durrani, A. M., Farr, S. J., and Kellaway, I. W. 1995. Influence of molecular-weight and formulation Ph on the precorneal clearance rate of hyaluronic-acid in the rabbit eye. Int. J. Pharm. 118:243-250.
53. Eliaz, R. E., and Szoka, F. C. 2001. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 61:2592-2601.
54. Elliott, G. R., Tak, C., Pellens, C., Ben-Efraim, S., and Bosta, I. L. 1988. Indomethacin stimulation of macrophage cytostasis against MOPC 315 tumor cells is inhibited by both prostaglandin E2 and norhydroguaiaretic acid, a lipooxygenase inhibitor. Cancer Immun. Immunother. 27:133-136.
55. Falk, R. E., Mikkelsaar, S., Asculai, S., Bryant, C., and Veenstra, J. 1992. Evaluation of prostaglandin (PGE) inhibitors combined with cytodestructive therapy in advanced neoplasia. Proc. Int. Clin. Hypertherm. Meeting. Loyon, France.
56. Fieldman, S. R., Fleischer, A. B., and McConnell, C. 1998. Most common dermatological problems identified by internists. Arch. Intern. Med. 158:726-730.
57. Figueiredo, F., Jones, G. M., Thouas, G. A., and Trounson, A. O. 2002. The effect of extracellular matrix molecules on mouse preimplantation embryo development in vitro. Repro. Fert. Devel. 14:443-451.
58. Fraser, J. R. E., Brown, T. J., and Laurent, T. C. 1998. Catabolism of hyaluronan. In The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives, ed. T. C. Laurent, 85-92, London: Portland Press.
59. Fraser, J. R. E., Kimpton, W. G., Pierscionek, B. K., and Cahill, R. N. P. 1993. The kinetics of hyaluronan in normal and acutely inflamed synovial joints-observations with experimental arthritis in sheep. Semin. Arth. Rheum. 22:9-17.
60. Fraser, J. R. E., Laurent, T. C., and Laurent, U. B. G. 1997. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242:27-33.
61. Fujii, K., Kawata, M., Kobayashi, Y., Okamoto, A., and Nishinari, K. 1996. Effects of the addition of hyaluronate segments with different chain lengths on the viscoelasticity of hyaluronic acid solutions. Biopolymers 38:583-591.
62. Furnus, C. C., de Matos, D. G., and Martinez, A. G. 1998. Effect of hyaluronic acid on development of in vitro produced bovine embryos. Theriogenology 49:1489-1499.
63. Gandolfi, S. A., Massari, A., and Orsoni, J. G. 1992. Low-molecular-weight sodium hyaluronate in the treatment of bacterial corneal ulcers. Graefes Arch. Clin. Exp. Ophthalmol. 230:20-23.
64. Gardner, D. K., Lane, M., Stevens, J., and Schoolcraft, W. B. 2003. Changing the start temperature and cooling rate in a slow-freezing protocol increases human blastocyst viability. Fertil. Steril. 79:407-410.
65. Gardner, D. K., Rodriegez-Martinez, H., and Lane, M. 1999. Fetal development after transfer is increased by replacing protein with the glycosaminoglycan hyaluronan for mouse embryo culture and transfer. Hum. Reprod. 14:2575-2580.
66. Ghosh, P., and Guidolin, D. 2002. Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: Are the effects molecular weight dependent? Semin. Arth. Rheum. 32:10-37.
67. Ghosh, P., Hutadilok, N., Adam, N., and Lentini, A. 1994. Interactions of hyaluronan (hyaluronic-acid) with phospholipids as determined by gel-permeation chromatography, multi-angle laser-light-scattering photometry and h-1-nmr spectroscopy. Int. J. Biol. Macromol. 16:237-244.
68. Ghosh, S., and Jassal, M. 2002. Use of polysaccharide fibres for modern wound dressings. Ind. J. Fibre Textile Res. 27:434-450.
69. Gibbs, D. A., Merrill, E. W., Smith, K. A., and Balazs, E. A. 1968. Rheology of hyaluronic acid. Biopolymers 6:777-791.
70. Goodison, S., Urquidi, V., and Tarin, D. 1999. CD44 cell adhesion molecules. J. Clin. Path.-Mol. Path. 52:189-196.
71. Gribbon, P., Heng, B. C., and Hardingham, T. E. 1999. The molecular basis of the solution properties of hyaluronan investigated by confocal fluorescence recovery after photobleaching. Biophys. J. 77:2210-2216.
72. Gribbon, P., Heng, B. C., and Hardingham, T. E. 2000. The analysis of intermolecular interactions in concentrated hyaluronan solutions suggest no evidence for chain-chain association. Biochem. J. 350:329-335.
73. Grimshaw, J., Kane, A., Trocha-Grimshaw, J., Douglas, A., Chakravrthy, U., and Archer, D. 1994. Electrophoresis 15:936-940.
74. Guidolin, D. D., Ronchetti, I. P., Lini, E., Guerra, D., and Frizziero, L. 2001. Morphological analysis of articular cartilage biopsies from a randomized. Clinical study comparing the effects of 500-730 kDa sodium hyaluronate (Hyalgan (R)) and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthr. Cartilage 9:371-381.
75. Gura, E., Huckel, M., and Muller, P. J. 1998. Specific degradation of hyaluronic acid and its Theological properties. Polym. Degrad. Stab. 59:297-302.
76. Gurny, R., Ibrahim, H., Aebi, A., Buri, P., Wilson, C. G., Washington, N., Edman, P., and Camber, O. 1987. Design and evaluation of controlled release systems for the eye. J. Control. Rel. 6:367-373.
77. Hamburger, M. I., Lakhanpal, S., Mooar, P. A., and Oster, D. 2003. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin. A rth. Rheum. 32:296-309.
78. Hawkins, C. L., and Davies, M. J. 1996. Direct detection and identification of radicals generated during the hydroxyl radical-induced degradation of hyaluronic acid and related materials. Free Radic. Biol. Med. 21:275-290.
79. Herrero-Vanrell, R., Fernandez-Carballido, A., Frutos, G., and Cadorniga, R. 2000. Enhancement of the mydriatic response to tropicamide by bioadhesive polymers. J. Ocul. Pharmacol. Ther. 16:419-428.
80. Hochberg, M. C. 2000. Role of intra-articular hyaluronic acid preparations in medical management of osteoarthritis of the knee. Semin. Arth. Rheum. 30:2-10.
81. How, M. J., and Long, V. J. W. 1969. Separation and fractionation of hyaluronic acid from humam synovial fluid on agrose gels. Clin. Chim. Acta 23:251-256.
82. Inoue, M., and Katakami, C. 1993. The effect of hyaluronic-acid on corneal epithelial-cell proliferation. Invest. Ophthal. Visual Sci. 34:2313-2315.
83. Iqbal, Z., et al. 1997. Determination of molecular weight of hyaluronic acid in bovine vitreous humour and Healon by high performance gel permeation chromatography and its depolymerization with ascorbic acid. Pharm. World Sci. 19:246-250.
84. Itano, N., and Kimata, K. 2002. Mammalian hyaluronan synthases. Iubmb Life 54:195-199.
85. Jaakma, U., Zhang, B. R., Larsson, B., Niwa, K., and RodriguezMartinez, H. 1997. Effects of sperm treatments on the in vitro development of bovine oocytes in semidefined and defined media. Theriogenology 48:711-720.
86. Jackson, C., Larsen, B., and McEwen, C. 1996. Comparison of most probable peak values as measured for polymer distributions by MALDI mass spectrometry and by size exclusion chromatography. Anal. Chem. 68:1303-1308.
87. Jang, G., Lee, B. C., Kang, S. K., and Hwang, W. S. 2003. Effect of glycosaminoglycans on the preimplantation development of embryos derived from in vitro fertilization and somatic cell nuclear transfer. Repro. Fert. Devel. 15:179-185.
88. Jarvinen, K., Jarvinen, T., and Urtti, A. 1995. Ocular absorption following topical delivery. Adv. Drug Dev. Rev. 16:3-19.
89. Jarvis, B., and Figgitt, D. P. 2003. Topical 3% diclofenac in 2.5% hyaluronic acid gel-a review of its use in patients with actinic keratoses. Am. J. Clini. Derm. 4:203-213.
90. Joly, T., Nibart, M., and Thibier, M. 1992. Hyaluronic-acid as a substitute for proteins in the deep-freezing of embryos from mice and sheep-an in vitro investigation. Theriogenology 37:473-480.
91. Juhlin, L. 1997. Hyaluronan in skin. J. Intern. Med. 242:61-66.
92. Kakehi, K. 2003. Hyaluronic acid: separation and biological implications. J. Chromat. 797:347-355.
93. Kano, K., Miyano, T., and Kato, S. 1998. Effects of glycosaminoglycans on the development of in vitro matured and fertilized porcine oocytes to the blastocyst stage in vitro. Biol. Reprod. 58:1226-1232.
94. Karamanos, N. K., and Hjerpe, A. 1997. High-performance capillary electrophoretic analysis of hyaluronan in effusions from human malignant mesotheliomal. J. Chromat. B: Biomed. Sci. Appl. 697:277-281.
95. Karim S., et al. 1996. The determination of the viscosity-average molecular weight of hyaluronan by capillary viscosity. In Hyaluronan in Drug Delivery-4th International Workshop, ed. D. Willoughby, 97-107. London: Royal Society of Medicine. Press.
96. Karim, S., Brown, M. B., Ingham, S., Martin, G. P, and Marriott, C. 1996. Rheological and molecular weight studies of hyaluronan. Eur. J. Pharm. Sci. 4:S175.
97. Karlsson, G., and Bergman, R. 2003. Determination of the distribution of molecular masses of sodium hyaluronan by high-performance anion-exchange chromatography. J. Chromat. A. 986:67-72.
98. Kaufmann, J., Mohle, K., Hofmann, H. J., and Arnold, K. 1998. Molecular dynamics study of hyaluronic acid in water. Theochem-J. Mol. Struc. 422:109-121.
99. Kaur, I. P., and Smitha, R. 2002. Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev. Ind. Pharm. 28:353-369.
100. Kelly, M. A., Goldberg, V. M., Healy, W. L., Pagnano, M. W., and Hamburger, M. I. 2003. Osteoarthritis and beyond: a consensus on the past, present, and future of hyaluronans in orthopedics. Orthopedics 26:1064-1079.
101. Kemmann, E. 1998. Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART)-quantification of risks as part of informed consent. Hum. Reprod. 13:1777.
102. Kim, A., Checkla, D. M., Dehazya, P., and Chen, W. L. 2003. Characterization of DNA-hyaluronan matrix for sustained gene transfer. J. Control. Rel. 90:81-95.
103. Kirwan, J. 2001. Is there a place for intra-articular hyaluronate in Osteoarthritis of the knee? Knee 8:93-101.
104. Knudson, W., Chow, G., and Knudson, C. B. 2002. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol. 21:15-23.
105. Kobayashi, Y., Okamoto, A., and Nishinari, K. 1994. Viscoelasticity of hyaluronic-acid with different molecular weights. Biorheology 31:235-244.
106. Koshiishi, I., Horikoshi, E., and Imanari, T. 1999. Quantification of hyaluronan and chondroitin/dermatan sulfates in the tissue sections on glass slides. Anal. Biochem. 267:222-226.
107. Lane, M., Maybach, J. M., Hooper, K., Hasler, J. F., and Gardner, D. K. 2003. Cryo-survival and development of bovine blastocysts are enhanced by culture with recombinant albumin and hyaluronan. Mol. Reprod. Dev. 64:70-78.
108. Langer, K., Mutschler, E., Lambrecht, G., Mayer, D., Troschau, G., Stieneker, F., and Kreuter, J. 1997. Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery-Part III: evaluation as drug delivery system for ophthalmic applications. Int. J. Pharm. 158:219-231.
109. Lapcik, L., Lapcik, L., De Smedt, S., Demester, J., and Chabrecek, P. 1998. Hyaluronan: preparation, structure, properties, and applications. Chem. Rev. 98:2663-2684.
110. Larsen, N. E., and Balazs, E. A. 1991. Drug delivery systems using hyaluronan and its derivatives. Adv. Drug Dev. Rev. 7:279-293.
111. Laurent, T. C., and Gergely, J. 1955. Light scattering studies on hyaluronic acid. J. Biol. Chem. 212:36-40.
112. Laurent, T. C. et al. 1960. Fraction of hyaluronic acid: the polydispersity of hyaluronic acid from the bovine vitreous body. Biochim. Biophys. Acta 42:476-485.
113. Laurent, T. C. 1970. Structure of hyaluronic acid. In Chemistry and the Molecular Biology of the Intracellular Matrix, ed. E. A. Balazs, 703-732, London: Academic Press.
114. Laurent, T. C. 1995. An early look at macromolecular crowding. Biophys. Chem. 57:7-14.
115. Laurent, T. C., and Fraser, J. R. E. 1992. Hyaluronan. FASEB J. 6:2397-2404.
116. Lebel, L. 1991. Clearance of hyaluronan from the circulation. Adv. Drug Dev. Rev. 7:221-235.
117. Lee, H. G., and Cowman, M. K. 1994. An agarose gel electrophoretic method for analysis of hyaluronan molecular weight distribution. Ana. Biochem. 219:278-287.
118. Lee, J. Y., and Spicer, A. P. 2000. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr. Opin. Cell Biol. 12:581-586.
119. Lim, S. T., Forbes, B., Berry, D. J., Martin, G. P., and Brown, M. B. 2002. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int. J. Pharm. 231:73-82.
120. Lim, S. T., Martin, G. P., Berry, D. J., and Brown, M. B. 2000. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J. Control. Rel. 66:281-292.
121. Lin, W., and Maibach, H. I. 1996. Percutaneous absorption of diclofenac in hyaluronic acid gel: in vitro study in human skin. In Hyaluronan in Drug Delivery, ed. D. Willoughby, 167-174. London: R. S. M. Press.
122. Liu, J., and Cowman, M. K. 2000. Thermal analysis of semi-dilute hyaluronan solutions. J. Thermal Anal. Calorimetry 59:547-557.
123. Lowry, K. M., and Beavers, E. M. 1994. Thermal-stability of sodium hyaluronate in aqueous-solution. J. Biomed. Mater. Res. 28:1239-1244.
124. Luo, Y. and Prestwich, G. D. 1999. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem. 10:755-763.
125. Luo, Y., Ziebell, M. R., and Prestwich, G. D. 2000. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 1:208-218.
126. Mabuchi, K., Obara, T., Ikegami, K., Yamaguchi, T., and Kanayama, T. 1999. Molecular weight independence of the effect of additive hyaluronic acid on the lubricating characteristics in synovial joints with experimental deterioration. Clin. Biomech. 14:352-356.
127. Maheu, E., Ayral, X., and Dougados, M. 2002. A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan((R)). Int. J. Clin. Pract. 56:804-813.
128. McEwan, L. E., and Smith, J. G. 1997. Topical diclofenac/hyaluronan gel in the treatment of solar keratoses. Aust. J. Derm. 38:187-189.
129. Mendichi, R., Schieroni, A. G., Grassi, C., and Re, A. 1998. Characterisation of ultra-high molar mass hyaluronan: 1. Off-line static methods. Polymer 39:6611-6620.
130. Menzel, E. J., and Farr, C. 1998. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett. 131:3-11.
131. Meyer, L., and Palmer, J. 1934. The polysaccharide of the vitreous humour. Biol. Chem. 107:629-634.
132. Milas, M., Rinaudo, M., Roure, I., Al Assaf, S., Phillips, G. O., and Williams, P. A. 2001. Comparative Theological behavior of hyaluronan from bacterial and animal sources with cross-linked hyaluronan (hylan) in aqueous solution. Biopolymers 59:191-204.
133. Miltner, O., Schneider, U., Siebert, C. H., Niedhart, C., and Niethard, F. U. 2002. Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis-a prospective clinical trial. Osteoarth. Cartilage 10:680-686.
134. Miyano, T., Hirooka, R. E., Kano, K., Miyake, M., Kusunoki, H., and Kato, S. 1994. Effects of hyaluronic-acid on the development of 1-cell and 2-cell porcine embryos to the blastocyst stage in vitro. Theriogenology 41:1299-1305.
135. Miyazaki, T., Miyauchi, S., Nakamura, T., Takeshita, S., and Horie, K. 1996. The effect of sodium hyaluronate on the growth of rabbit cornea epithelial cells in vitro. J. Ocul. Pharmacol. Ther. 12:409-415.
136. Miyazaki, T., Yomota, C., and Okada, S. 1998. Change in molecular weight of hyaluronic acid during measurement with a cone-plate rotational viscometer. J. Appl. Polym. Sci. 67:2199-2206.
137. Miyazaki, T., Yomota, C., and Okada, S. 2001. Hyaluronate depolymerization following thermal decomposition of oxytetracycline. Chem. Pharma. Bull. 49:118-122.
138. Mo, Y., Takaya, T., Nishinari, K., Kubota, K., and Okamoto, A. 1999. Effects of sodium chloride, guanidine hydrochloride, and sucrose on the viscoelastic properties of sodium hyaluronate solutions. Biopolymers 50:23-34.
139. Moreira, C. A., Armstrong, D. K., Jelliffe, R. W., Moreira, A. T., Woodford, C. C., Liggett, P. E., and Trousdale, M. D. 1991a. Sodium hyaluronate as a carrier for intravitreal gentamicin-an experimental-study. Acta Ophthalmol. (Copenh). 69:45-49.
140. Moreira, C. A., Moreira, A. T., Armstrong, D. K., Jelliffe, R. W., Woodford, C. C., Liggett, P. E., and Trousdale, M. D. 1991b. In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. Acta Ophthalmol. (Copenh). 69:50-56.
141. Moreland, L. W. 2003. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arth. Res. Ther. 5:54-67.
142. Morimoto, K., Metsugi, K., Katsumata, H., Iwanaga, K., and Kakemi, M. 2001. Effects of low-viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev. Ind. Pharm. 27:365-371.
143. Morimoto, K., Yamaguchi, H., Iwakura, Y., Morisaka, K., Ohashi, Y., and Nakai, Y. 1991. Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analog. Pharm. Res. 8:471-474.
144. Moy, R. L. 2000. Clinical presentation of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 42:S8-S10.
145. Nazir, T., Martin, G. P., and Brown, M. B. 2001. Dermal delivery of cyclosporin A entrapped liposomal gels-preformulation Franz cell diffusion studies using silastic membranes. Pharm. Sci. 3(suppl.):1429.
146. Ng, C. K., Handley, C. J., Preston, B. N., and Robinson, H. C. 1992. The extracellular processing and catabolism of hyaluronan in cultured adult articular-cartilage expiants. Arch. Biochem. Biophys. 298:70-79.
147. Ogston A. G., and Stainer J. E. 1950. On the state of hyaluronic acid in synovial fluid. Biochem. J. 46:364-376.
148. Ogston, A. G., and Stainer, J. E. 1951. The dimension of the particle of hyaluronic acid complex in synovial fluid. Biochem. J. 49:585-590.
149. Ogston, A. G., and Stainer, J. E. 1952. Further observation on the preparation and compasition of the hyaluronic acid complex of ox synovial fluid. Biochem. J. 52:149-156.
150. Ortonne, J. P., 1996. A controlled study of the activity of hyaluronic acid in the treatment of venous leg ulcers. J. Dermal. Treat. 7:75-81.
151. Panie, W. R., 1981. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch. Otolaryngol. 107:658-663.
152. Pasquali Ronchetti, I., Quaglino, D., Mori, G., Bacchelli, B., and Ghosh, P. 1997. Hyaluronan-phospholipid interactions. J. Struct. Biol. 120:1-10.
153. Peer, D., Florentin, A., and Margalit, R. 2003. Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochimi. Biophys. Acta-Biomemb. 1612:76-82.
154. Peer, D., and Margalit, R. 2000. Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch. Biochem. Biophys. 383:185-190.
155. Pigman, W., Rizvi, S., and Holley, H. 1961. Preparation and stability of hyaluronic acid. Biochim. Biophys. Acta-Biomemb. 46:100.
156. Platzer, M., Ozegowski, J. H., and Neubert, R. H. H. 1999. Quantification of hyaluronan in pharmaceutical formulations using high performance capillary electrophoresis and the modified uronic acid carbazole reaction. J. Pharm. Biomed. Anal. 21:491-496.
157. Poggi, M. M., Klein, M. B., Chapo, G. A., and Cuono, C. B. 1999. Effects of cryopreservation and deconstruction on the dermal glycosaminoglycan content of human skin. J. Burn Care Rehab. 20:201-206.
158. Ponta, H., Sherman, L., and Herrlich, P. A. 2003. CD44: from adhesion molecules to signalling regulators. Nat. Revi. Mol. Cell Biol. 4:33-45.
159. Praest, B. M. et al. 1997. Assay of synovial fluid parameters: hyaluronan concentration as a potential marker for joint diseases. Clin. Chim. Acta. 266:117-128.
160. Prevo, R., Banerji, S., Ferguson, D. J. P., Clasper, S., and Jackson, D. G. 2001. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J. Biol. Chem. 276:19420-19430.
161. Prisell, P. T., Camber, O., Hiselius, J., and Norstedt, G. 1992. Evaluation of hyaluronan as a vehicle for peptide growth factors. Int. J. Pharm. 85:51-56.
162. Pritchard, K., Lansley, A. B., Martin, G. P., Helliwell, M., Marriott, C., and Benedetti, L. M. 1996. Evaluation of the bioadhesive properties of hyaluronan derivatives: detachment weight and mucociliary transport rate studies. Int. J. Pharm. 129:137-145.
163. Reed, C. E. L. et al. 1989. The effects of pH on hyaluronate as observed by light scattering. Biopolymers 28:1981-2000.
164. Reed, C. E., and Reed, W. F. 1989. Light-scattering power of randomly cut random coils with application to the determination of depolymerization rates. J. Chem. Phys. 91:7193-7199.
165. Risberg, B. 1997. Adhesions: preventive strategies. Eur. J. Surg. 163:32-39.
166. Saettone, M. F., Chetoni, P., Torracca, M. T., Burgalassi, S., and Giannaccini, B. 1989. Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic-acid. Int. J. Pharm. 51:203-212.
167. Saettone, M. F., Giannaccini, B., Chetoni, P., Torracca, M. T., and Monti, D. 1991. Evaluation of high-molecular-weight and low-molecular-weight fractions of sodium hyaluronate and an ionic complex as adjuvants for topical ophthalmic vehicles containing pilocarpine. Int. J. Pharm. 72:131-139.
168. Saettone, M. F., Monti, D., Torracca, M. T., and Chetoni, P. 1994. Mucoadhesive ophthalmic vehicles-evaluation of polymeric low-viscosity formulations. J. Ocul. Pharmacol. 10:83-92.
169. Sakai, S., Yasuda, R., Sayo, T., Ishikawa, O., and Inoue, S. 2000. Hyaluronan exists in the normal stratum corneum. J. Invest. Dermatol. 114:1184-1187.
170. Sakurai, K., Andoh, M., Yamada, M., Kodera, Y., Nishimura, H., Hiroto, M., Matsushima, A., Aoyama, M., Yamamoto, H., and Inada, Y. 1997a. Suppression of ischemic edema in mice by manganese-hyaluronate conjugate. Jpn. J. Pharmacol. 74:117-120.
171. Sakurai, K., Miyazaki, K., Kodera, Y., Nishimura, H., Shingu, M., and Inada, Y. 1997b. Anti-inflammatory activity of superoxide dismutase conjugated with sodium hyaluronate. Glycoconj. J. 14:723-728.
172. Sasaki, H., Yamamura, K., Nishida, K., Nakamura, J., and Ichikawa, M. 1996. Delivery of drugs to the eye by topical application. Prog. Retin. Eye Res. 15:583-620.
173. Schartz, R. A. 1997. The actinic keratoses. A perspective and update. Dermatol. Surg. 23:1009-1019.
174. Scott, J. E. 1984. The periphery of the developing collagen fibril-quantitative relationships with dermatan sulfate and other surface-associated species. Biochem. J. 218:229-233.
175. Scott, J. E., and Heatley, F. 1999. Hyaluronan forms specific stable tertiary structures in aqueous solution: a C-13 NMR study. Proc. Natl. Acad. Sci. USA 96:4850-4855.
176. Scott, J. E., and Heatley, F. 2002. Biological properties of hyaluronan in aqueous solution are controlled and sequestered by reversible tertiary structures, defined by NMR spectroscopy. Biomacromolecules 3:547-553.
177. Seno, N., Anno, K., Kondo, S., Nagase, S., and Saito, S. 1970. Improved method for electrophoretic separation and rapid quantitation of isomeric chondroitin sulfates on cellulose acetate strips. Anal. Biochem. 1970:197-202.
178. Sheehan, J. K., Arundel, C., and Phelps, C. F. 1983. Effect of the cations sodium, potassium and calcium on the interaction of hyaluronate chains-a light-scattering and viscometric study. Int. J. Biol. Macromol. 5:222-228.
179. Shimada, E., and Matsumura, G. 1975. Viscosity and molecular weight of hyaluronic acids. J. Biochem. 78:513-517.
180. Shinomiya, K., Hoshi, Y., and Imanari, T. 1989. Sensitive detection of unsaturated disaccharides from chondroitin sulfates by thin-layer chromatography as their dansylhydrazine derivatives. J. Chromatogr. 462:471-474.
181. Simon, A., Safran, A., Revel, A., Aizenman, E., Reubinoff, B., Porat-Katz, A., Lewin, A., and Laufer, N. 2003. Hyaluronic acid can successfully replace albumin as the sole macromolecule in a human embryo transfer medium. Fertil. Steril. 79:1434-1438.
182. Soldati, D., Rahm, F., and Pasche, P. 1999. Mucosal wound healing after nasal surgery. A controlled clinical trial on the efficacy of hyaluronic acid containing cream. Drugs Exp. Clin. Res. 25:253-261.
183. Spicer, A. P., and Nguyen, T. K. 1999. Mammalian hyaluronan synthases: investigation of functional relationships in vivo. Biochem. Soc. Trans. 27:109-115.
184. Stiebel-Kalish, H., Gaton, D. D., Weinberger, D., Loya, N.,
185. Suchanek, E., Simunic, V., Juretic, D., and Grizelj, V. 1994. Follicular-fluid contents of hyaluronic-acid, follicle-stimulating-hormone and steroids relative to the success of in-vitro fertilization of human oocytes. Fertil. Steril. 62:347-352.
186. Sundblad, L. 1965. Glycosaminoglycans and glycoproteins in synovial fluid. In The Amino Sugars. The Chemistry and Biology of the Compounds Containing the Amino Sugars, eds. E. A. Balazs and R. W. Jeanloz, 229-250, New York: Academic Press.
187. Surendrakumar, K., Martyn, G. P., Hodgers, E. C. M., Jansen, M., and Blair, J. A. 2003. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Rel. 91:385-394.
188. Surini, S., Akiyama, H., Morishita, M., Nagai, T., and Takayama, K. 2003a. Release phenomena of insulin from an implantable device composed of a polyion complex of chitosan and sodium hyaluronate. J. Control. Rel. 90:291-301.
189. Surini, S., Akiyama, H., Morishita, M., Takayama, K., and Nagai, T. 2003b. Polyion complex of chitosan and sodium hyaluronate as an implant device for insulin delivery. Stp Pharma Sciences 13:265-268.
190. Takayama, K., Hirata, M., Machida, Y., Masada, T., Sannan, T., and Nagai, T. 1990. Effect of interpolymer complex-formation on bioadhesive property and drug release phenomenon of compressed tablet consisting of chitosan and sodium hyaluronate. Chemi. Pharm. Bull. 38:1993-1997.
191. Tammi, M. I., Day, A. J., and Turley, E. A. 2002. Hyaluronan and homeostasis: a balancing act. J. Biol. Chem. 277:4581-4584.
192. Tammi, R., Agren, U. M., Tuhkanen, A. L., and Tammi, M. 1994. Hyaluronan metabolism in skin-introduction. Hyaluronan Metabol. in Skin 29:1-77.
193. Tammi, R., Saamanen, A. M., Maibach, H. I., and Tammi, M. 1991. Degradation of newly synthesized high molecular mass hyaluronan in the epidermal and dermal compartments of human skin in organ culture. J. Invest. Dermatol. 97:126-130.
194. Tani, E., Katakami, C., and Negi, A. 2002. Effects of various eye drops on corneal wound healing after superficial keratectomy in rabbits. Jpn. J. Ophthal. 46:488-495.
195. Tascioglu, F., and Oner, C. 2003. Efficacy of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis. Clin. Rheumatol. 22:112-117.
196. Tilden, A. B., and Balch, C. M. 1982. Immune modulatory effects of indomethacin in melanoma are not related to prostaglandin E2-mediated suppression. Surgery 92:528.
197. Toida, T., Shima, M., Azumaya, S., Maruyama, T., Toyoda, H., Imanari, T., and Linhardt, R. J. 1997. Detection of glycosaminoglycans as a copper(II) complex in high-performance liquid chromatography. J. Chromat. A. 787:266-270.
198. Tokita, Y., Ohshima, K., and Okamoto, A. 1997. Degradation of hyaluronic acid during freeze drying. Polym. Degrad. Stab. 55:159-164.
199. Tokita, Y., and Okamoto, A. 1995. Hydrolytic degradation of hyaluronic-acid. Polym. Degrad. Stab. 48:269-273.
200. Tool, B. P. 2001. Hyaluronan in morphogenesis. Sem. Cell Devel. Biol. 12:79-87.
201. Toole, B. P., Wight, T. N., and Tammi, M. I. 2002. Hyaluronan-cell interactions in cancer and vascular disease. J. Biol. Chem. 277:4593-4596.
202. Turino, G. M., and Cantor, J. O. 2003. Hyaluronan in respiratory injury and repair. Am. J. Respir. Crit. Care Med. 167:1169-1175.
203. Turley, E. A., Noble, P. W., and Bourguignon, L. Y. W. 2002. Signaling properties of hyaluronan receptors. J. Biol. Chem. 277:4589-4592.
204. Uthman, I., Raynauld, J. P., and Haraoui, B. 2003. Intra-articular therapy in osteoarthritis. Postgrad. Med. J. 79:449-453.
205. Vanos, H. C., Drogendijk, A. C., Fetter, W. P. F., Heijtink, R. A., and Zeilmaker, G. H. 1991. The influence of contamination of culture-medium with hepatitis-B virus on the outcome of invitro fertilization pregnancies. Am. J. Obstet. Gynecol. 165:152-159.
206. Vazquez, J. R., Short, B., Findlow, A. H., Nixon, B. P., Boulton, A. J. M., and Armstrong, D. G. 2003. Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res. Clin. Pract. 59:123-127.
207. Vercruysse, K. P., Lauwers, A. R., and Demeester, J. M. 1995. Absolute and empirical determination of the enzymatic-activity and kinetic investigation of the action of hyaluronidase on hyaluronan using viscosimetry. Biochem. J. 306:153-160.
208. Vercruysse, K. P., and Prestwich, G. D. 1998. Hyaluronate derivatives in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 15:513-555.
209. Volpi, N., and Maccari, F. 2002. Detection of submicrogram quantities of glycosaminoglycans on agarose gels by sequential staining with toluidine blue and Stains-All. Electrophoresis. 23:4060-4066.
210. Volpi, N. 2000. Hyaluronic acid and chondroitin sulfate unsaturated disaccharides analysis by high-performance liquid chromatography and fluorimetric detection with dansylhydrazine. Anal. Biochem. 277:19-24.
211. Wedlock, D. J., Phillips, G. O., Davies, A., Gormally, J., and Wynjones, E., 1983. Depolymerization of sodium hyaluronate during freeze-drying. Int. J. Biol. Macromol. 5:186-188.
212. Wolf, J. E., Taylor, J. R., Tschen, E., and Kang, S. W. 2001. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int. J. Dermatol. 40:709-713.
213. Wuthrich, R. P. 1999. The proinflammatory role of hyaluronan-CD44 interactions in renal injury. Nephrol. Dial. Transplant. 14:2554-2556.
214. Yerushalmi, N., Arad, A., and Margalit, R. 1994. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug-delivery in wound-healing. Arch. Biochem. Biophys. 313:267-273.
215. Yerushalmi, N., and Margalit, R., 1998. Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch. Biochem. Biophys. 349:21-26.
216. Yeung, B., and Marecak, D. 1999. Molecular weight determination of hyaluronic acid by gel filtration chromatography coupled to matrix-assisted laser desorption ionisation mass spectrometry. J. Chromat. A 852:573-581.
217. Yun, Y. H., Goetz, D. J., Yellen, P., and Chen, W. 2004. Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials 25:147-157.
218. Zhou, B., Weigel, J. A., Fauss, L. A., and Weigel, P. H. 2000. Identification of the hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 275:37733-37741.
219. Zhu, Y. X., and Granick, S. 2003. Biolubrication: hyaluronic acid and the influence on its interfacial viscosity of an antiinflammatory drug. Macromolecules 36:973-976.